The current price of ABSI is $9.39 — it has decreased by 10.40% since the previous close. Data as of Nov 5, 2026.
ABSI is down 17.70% over the past week, down 18.56% over the past month and up 146.46% over the past year. The price is above its 200-day moving average of $6.60.
Analysts' average 12-month price target for ABSI is $13.67, which implies 45.58% upside from the current price. Individual estimates range from $10.00 to $16.00.
Of the 12 analysts covering Absci Corporation, 2 rate it a strong buy, 9 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Absci Corporation has a market capitalization of $1.61B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Absci Corporation posted a loss of $0.18 per share against an estimate of -$0.191, beating expectations by 5.77%. Upcoming reports are listed in the earnings calendar.
Absci Corporation reported revenue of $300K in its most recent quarter, which has decreased by 49.41% compared with the same quarter a year earlier. Analysts had expected $919.58K.
Absci Corporation has not paid any dividends over the past year.
Companies most comparable to Absci Corporation include AbCellera Biologics Inc. and Generate Biomedicines, Inc.
In the latest trading session ABSI moved between $9.00 and $10.13, a range of 12.03% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Absci Corporation shows a sell rating today and a neutral rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Absci Corporation is buy. Technical ratings are indicators, not investment advice.
Over the past 52 weeks ABSI has traded between $2.24 and $12.54. The current price is 25.12% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.